title: Hodgkin's lymphoma following treatment with etanercept in ankylosing spondylitis.
abstract: It has been well known that anti-TNF drugs might increase lymphoma risk in rheumatoid arthritis (RA), where the rate of lymphoma has already been increased. However, unlike RA, an increased rate of lymphoma has not been reported in ankylosing spondylitis (AS). Hereby, we present a case with AS developing Hodgkin's lymphoma (HL) following 6 months of etanercept treatment. Pathological analysis revealed mixed cellular type of HL. Although we report a single case, it should be kept in mind that anti-TNF drugs might cause lymphoma development not only in RA, but also in AS.
authors.affiliation: Internal Medicine-Rheumatology Division, Ege University School of Medicine Hospital, Izmir, Turkey. kenan.aksu@ege.edu.tr
authors.forename: Kenan
authors.initials: K
authors.lastname: Aksu
authors.forename: Ayhan
authors.initials: A
authors.lastname: Donmez
authors.forename: Yesim
authors.initials: Y
authors.lastname: Ertan
authors.forename: Gokhan
authors.initials: G
authors.lastname: Keser
authors.forename: Vedat
authors.initials: V
authors.lastname: Inal
authors.forename: Gonca
authors.initials: G
authors.lastname: Oder
authors.forename: Murat
authors.initials: M
authors.lastname: Tombuloglu
authors.forename: Yasemin
authors.initials: Y
authors.lastname: Kabasakal
authors.forename: Eker
authors.initials: E
authors.lastname: Doganavsargil
mesh_terms: D000328:Adult; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D000068800:Etanercept; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000209:etiology* / Q000473:pathology; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D008297:Male; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept